虚拟筛选
可药性
泛素
蛋白酶
化学
酶
IC50型
对接(动物)
活动站点
生物化学
计算生物学
癌症研究
生物
体外
药物发现
医学
基因
护理部
作者
Hong‐Ju Li,Yujie Sun,Hua Yin,Yuzhu Zhang,Junhong Yu,Ning Hou,Peng Wang,Huicong Liang,Aowei Xie,Xiaohong Wang,Lin Liao,Ximing Xu
标识
DOI:10.1080/07391102.2024.2316779
摘要
Ubiquitin-specific protease 7 (USP7) is a promising prognostic and druggable target for cancer therapy. Inhibition of USP7 can activate the MDM2-P53 signaling pathway, thereby promoting cancer cell apoptosis. This study based on watvina molecular docking of virtual screening method and biological evaluation found the new USP7 inhibitors targeting catalytic active site. Three hits were screened from 3760 natural products and validated as USP7 inhibitors by enzymatic and kinetic assays. The IC50 values of scutellarein (Scu), semethylzeylastera (DML) and salvianolic acid C (SAC) were 3.017, 6.865 and 8.495 μM, respectively. Further, we reported that the hits could downregulate MDM2 and activate p53 signal pathway in HCT116 cells. Molecular dynamics simulation was used to investigate the binding mechanism of USP7 to Scu, the compound with the best performance, which formed stable contact with Val296, Gln297, Phe409, Tyr465 and Tyr514. These interactions are essential for maintaining the biological activity of Scu. Three natural products are suitable as lead compounds for the development of novel USP7 inhibitors, especially anti-colon cancer drugs.
科研通智能强力驱动
Strongly Powered by AbleSci AI